Literature DB >> 18228583

Role of mechanical stress in crystallization and relaxation behavior of amorphous indomethacin.

Chandan Bhugra1, Rama Shmeis, Michael J Pikal.   

Abstract

Even within an amorphous state, high energy sites can be generated due to sample handling and variations in preparation techniques can result in variation in these high energy sites. Such small handling variations may result in changes in physical properties and physical stability. The aim of this work is to characterize the differences in crystallization tendencies of amorphous Indomethacin arising from minor variations in sample handling. Amorphous Indomethacin was prepared by three variations on melt quenching using liquid nitrogen. Crystallization was studied by annealing the samples at various temperatures above T(g) and then using DSC to observe the melt of the polymorph crystallized during annealing. The "No stress" samples showed only T(g) whereas other samples showed three events: T(g), crystallization and melting. Even at high temperatures (90 degrees C), crystallization was not reproducible in the "No Stress" sample. However, crystallization at 90 degrees C was reproducible and immediate in samples with mechanical stress. At lower temperatures, differences were observed in extent of crystallization and in polymorph formed, which demonstrated the introduction of nuclei due to sample handling. Differences were also observed in relaxation kinetics of the different sample preparations. However, at 35 degrees C the relaxation kinetics were similar but with crystallization behavior being different. (c) 2008 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18228583     DOI: 10.1002/jps.21291

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Origin of two modes of non-isothermal crystallization of glasses produced by milling.

Authors:  Sayantan Chattoraj; Chandan Bhugra; Chitra Telang; Li Zhong; Zeren Wang; Changquan Calvin Sun
Journal:  Pharm Res       Date:  2011-12-16       Impact factor: 4.200

2.  Effect of compression on non-isothermal crystallization behaviour of amorphous indomethacin.

Authors:  Zelalem Ayenew; Amrit Paudel; Patrick Rombaut; Guy Van den Mooter
Journal:  Pharm Res       Date:  2012-05-26       Impact factor: 4.200

3.  Investigation of the milling-induced thermal behavior of crystalline and amorphous griseofulvin.

Authors:  Niraj S Trasi; Stephan X M Boerrigter; Stephen Robert Byrn
Journal:  Pharm Res       Date:  2010-05-18       Impact factor: 4.200

4.  A slow cooling rate of indomethacin melt spatially confined in microcontainers increases the physical stability of the amorphous drug without influencing its biorelevant dissolution behaviour.

Authors:  Line Hagner Nielsen; Stephan Sylvest Keller; Anja Boisen; Anette Müllertz; Thomas Rades
Journal:  Drug Deliv Transl Res       Date:  2014-06       Impact factor: 4.617

5.  Solid-State NMR Investigation of Drug-Excipient Interactions and Phase Behavior in Indomethacin-Eudragit E Amorphous Solid Dispersions.

Authors:  Joseph W Lubach; Jonathan Hau
Journal:  Pharm Res       Date:  2018-02-20       Impact factor: 4.200

6.  A novel drug-drug coamorphous system without molecular interactions: improve the physicochemical properties of tadalafil and repaglinide.

Authors:  Meiling Su; Yanming Xia; Yajing Shen; Weili Heng; Yuanfeng Wei; Linghe Zhang; Yuan Gao; Jianjun Zhang; Shuai Qian
Journal:  RSC Adv       Date:  2020-01-02       Impact factor: 4.036

7.  A Novel Desloratadine-Benzoic Acid Co-Amorphous Solid: Preparation, Characterization, and Stability Evaluation.

Authors:  Ahmad Ainurofiq; Rachmat Mauludin; Diky Mudhakir; Sundani Nurono Soewandhi
Journal:  Pharmaceutics       Date:  2018-07-06       Impact factor: 6.321

Review 8.  Crystallization Tendency of Pharmaceutical Glasses: Relevance to Compound Properties, Impact of Formulation Process, and Implications for Design of Amorphous Solid Dispersions.

Authors:  Kohsaku Kawakami
Journal:  Pharmaceutics       Date:  2019-05-01       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.